Results for Chronic Traumatic Encephalopathy

New York Times reporting: The AstraZeneca-Oxford vaccine has been deployed against COVID-19 in at least 115 countries, some of them for several months now. But it was not until a few cases of a rare blood-clotting disorder — some fatal — emerged within the past month or so that many European nations began to rethink its use across all age groups. Public health experts, however, have expressed concern that publicity surrounding the rare vaccine-related reactions will fuel hesitancy. They continue to emphasize that the AstraZeneca-Oxford vaccine’s benefits far outweigh the risks. In many nations, it is the only vaccine available.